With a strategic refocus underway, GlaxoSmithKline Plc delivered revenue growth of 4% in the third quarter and a higher operating margin of 23.9%. The company is forecasting earnings per share growth of 3% to 5% for the year as a whole, expressed in constant exchange rates.
